Organization Profile

You just read:

Health Canada approves DAKLINZA™ (daclatasvir) for the treatment of chronic Hepatitis C infection across multiple genotypes including genotype 3

News provided by

Bristol-Myers Squibb Canada

Aug 20, 2015, 05:59 ET